

to a patient in need of such treatment a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, in combination with a β -lactam antibiotic.

[0013] In yet another aspect, the present invention provides a method of sensitising *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* to treatment with a β -lactam antibiotic, the method comprising the administration of a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, in combination with the β -lactam antibiotic. In an embodiment, the present invention provides a method of sensitising *Strenotrophomonas maltophilia* to treatment with a β -lactam antibiotic, the method comprising the administration of a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, in combination with the β -lactam antibiotic.

[0014] In yet another aspect, the present invention provides a method of potentiating the effect of a β -lactam antibiotic for the treatment of *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infections, the method comprising the administration of a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, in combination with the β -lactam antibiotic. In an embodiment, the present invention provides a method of potentiating the effect of a β -lactam antibiotic for the treatment of *Strenotrophomonas maltophilia* infections, the method comprising the administration of a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, in combination with the β -lactam antibiotic.

[0015] The present invention also provides a combination product comprising a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, and a β -lactam antibiotic. In particular, there is provided a combination product comprising a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, and a β -lactam antibiotic in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

[0016] The combination product of the invention is for use in the treatment of *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infections. Suitably, the combination product of the invention is for use in the treatment of *Strenotrophomonas maltophilia* infections.

[0017] The combination product of the present invention provides for the administration of a β -lactamase inhibitor of Formula I as defined herein, or a pharmaceutically acceptable salt thereof, and a β -lactam antibiotic. The combination product may be in the form of a combined preparation of the β -lactamase inhibitor and the β -lactam antibiotic. The combination product may also include one or more additional antibiotics or β -lactamase inhibitors. Alternatively, the combination product may comprise a kit of parts comprising separate formulations of the β -lactamase inhibitor and β -lactam antibiotic. The separate formulations of the β -lactamase inhibitor and β -lactam antibiotic may be administered sequentially, separately and/or simultaneously. In one embodiment, the separate formulations of the β -lactamase inhibitor and β -lactam antibiotic of the combination product are administered simultaneously (optionally repeatedly). In another embodiment, the separate formulations of the β -lactamase inhibitor and β -lactam antibiotic of the combination product are administered sequentially (option-

ally repeatedly). In another embodiment, the separate formulations of the β -lactamase inhibitor and β -lactam antibiotic of the combination product are administered separately (optionally repeatedly). Where the administration of the separate formulations of the β -lactamase inhibitor and β -lactam antibiotic of the combination product is sequential or separate, the delay in administering the second formulation should not be such as to lose the beneficial effect of the combination therapy. Thus, the present invention provides a combination product comprising a β -lactamase inhibitor, or a pharmaceutically-acceptable salt thereof, and a β -lactam antibiotic, or a pharmaceutically-acceptable salt thereof, for use sequentially, separately and/or simultaneously in the treatment of *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infections (suitably in the treatment of *Strenotrophomonas maltophilia* infections).

[0018] In another aspect, the present invention relates to a pharmaceutical composition suitable for use in the treatment of a *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infection which comprises a combination therapeutic product, as defined herein, in association with a pharmaceutically-acceptable excipient or carrier. In an embodiment, present invention relates to a pharmaceutical composition suitable for use in the treatment of a *Strenotrophomonas maltophilia* infection which comprises a combination therapeutic product, as defined herein, in association with a pharmaceutically-acceptable excipient or carrier.

[0019] In another aspect, there is provided a combination product which comprises a kit of parts comprising the following components:

[0020] a β -lactamase inhibitor, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier; and

[0021] a β -lactam antibiotic, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier,

[0022] wherein the components are provided in a form which is suitable for sequential, separate and/or simultaneous administration.

[0023] The kit of parts is for the treatment of *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infections (suitably for the treatment of *Strenotrophomonas maltophilia*, infections).

[0024] In one embodiment the kit of parts comprises:

[0025] a first container comprising a β -lactamase inhibitor, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier;

[0026] a second container comprising a β -lactam antibiotic, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier; and

[0027] a container means for containing said first and second containers.

[0028] In one embodiment, the kit of parts further comprises instructions on how to administer the components sequentially, separately and/or simultaneously. In one embodiment, the kit of parts further comprises instructions indicating that the combination product can be used in the treatment of *Strenotrophomonas maltophilia*, tuberculosis and/or *Pseudomonas* infections.

[0029] Features, including optional, suitable, and preferred features in relation to one aspect of the invention may